Biomaterial science is one of the major pillars of successful 3D printed solutions for healthcare. In this webinar, we invited stakeholders from academia, industry, larger chemical and material companies, and rising startups to give you a comprehensive view of where material science technology for healthcare 3D printing is at. We aim to provide information with enough breadth and depth that is suitable for both the general public and industry experts. We will also have breakout rooms after the webinar presentations for networking purposes, which will last around 30 minutes. This serves to network freely and also to connect Pitch3D startups and investors during the breakout session, and you can apply here. The on-demand recording will be available here after the event.
Astrid Ahlinder holds a PhD in Polymer technology from KTH Royal institute of technology in Sweden. She trained as a Biomedical Engineer in Glasgow, UK, during her PhD she looked into the effect of processing parameters when 3D printing degradable polymer for soft tissue engineering; the synergy between inherent material properties, processing parameters and design of the final structures. She has taken part in starting up AKIRA Science, a spin off from the research group at KTH looking to supply researchers and surgeons with degradable pliable polymers and 3D printed structures for tissue engineering. Her primary interest is the relationship between material science, processing and tissue engineering.
Balaji Prabhu is Director Global R&D, 3D printing at Dentsply Sirona.
His experience in medical device and biomaterials includes various leadership roles at Stryker Orthopaedics and Evonik Corp.
His diverse experience includes R&D, scale-up, marketing, manufacturing and business development leading multiple medical device innovations from concept to commercialization.
Balaji led the setting up and commercialization of Evonik’s Medical Device Competence Center (MDCC) in Birmingham, Alabama which is also the 3D printing Center of Excellence for polymers. His career involves bringing various cutting-edge platform technologies including 3D Printing through successful commercialization for human use.
He holds Graduate degrees in Materials Science Engineering, Executive Technology Mgmt., and an Executive MBA in Innovation & Technology Management.
Talk title: Collagen BioInk Platform for 3D Bioprinting of Tissues and Organs
Nadav Orr, PhD, VP R&D at CollPlant Ltd, joined CollPlant in 2014. He is leading a multidisciplinary R&D team towards the development of technology platforms and clinical applications in the field of regenerative medicine. Prior to this, Nadav served as an Associate Director and Manager of an R&D group at Omrix Biopharmaceuticals Ltd., a subsidiary of ETHICON Biosurgery, a Johnson & Johnson company. While at Omrix, Nadav led an international team developing hemostatic combination products and led base business support for production processes and products. Nadav holds a PhD in immunology from the Weizmann Institute of Science.
Prior to founding OPM in 2000, CEO and Chairman Scott DeFelice was co-founder and Vice President of Marketing at Oxford Polymers, a compounder of engineered thermoplastics, where he led the firm’s innovation, strategy, and business development activities.
Mr. DeFelice has grown OPM to become a recognized leader in 3D printing and high performance additive manufacturing (HPAM™). A proven entrepreneur in the fields of cutting edge materials and additive manufacturing, DeFelice’s company has developed a range of advanced materials technology focused on a high performance polymer, poly-ether-ketone-ketone (PEKK), and delivers enterprise level, functional end-use products to the biomedical, aerospace and industrial markets as the first company to successfully apply additive manufacturing solutions to PEKK.
In addition to OPM, Mr. DeFelice serves on the Sustainability Committee of America Makes – the National Additive Manufacturing Innovation Institute. Mr. DeFelice holds a BA from the University of Connecticut and an MSc from the University of Strathclyde, Scotland. He is married with two children and is active in cycling and golf.
Joe is currently a biomedical engineer and PhD Candidate at Mount Sinai, working in the labs of Drs. Kevin Costa and Junqian Xu, in addition to being the lead engineer with the Sinai BioDesign innovation team and helping run the MSIG and GRO-Biotech student groups. Previously, he worked at 3D Systems on technical development in the consumer marketing department and as a liaison with engineering project management teams, in addition to an earlier stint at experiential marketing firm Affinitive.
Joe received his bachelors in Biomedical Engineering from Macaulay Honors College at The City College of New York, where he also remains active in the Zahn Innovation Center, an on-campus tech startup incubator.
He has also been involved in several startup ventures in the hardware and biotech spaces. Several years ago, Joe took Proto-Sauce, through NYCEDC’s Futureworks Incubator, with the goal of developing new materials for resin-based 3D printing. More recently, he had the privilege to serve as the CTO of BioSapien, using advanced manufacturing to create new devices for the treatment of cancer. Beyond Joe’s direct startup work, he has also continued to participate in Futureworks and other New York City startup programs as a mentor.